Compare Gilead Sciences, Inc. (GILD) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $132.95 (market cap $163.51B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.89. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | TLT | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $92.06 |
52-Week Low | $108.22 | $83.02 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
The iShares 20+ Year Treasury Bond ETF (TLT) trades at $83.80, down 0.33% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. Recent news highlights comparisons with other fixed-income ETFs and discussions about Treasury rate risk, while the fund continues its regular dividend distribution schedule through mid-2026.
TLT presents a defensive fixed-income opportunity amid market volatility, offering exposure to long-term Treasury bonds with current yields significantly higher than pre-crisis levels. However, investors face duration risk from potential Fed policy shifts and competition from higher-yielding alternatives, requiring careful consideration of interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
